India, March 26 -- Vivani Medical, Inc. (VANI) Wednesday announced encouraging data from the preclinical study of NPM-139 for chronic weight management in obese and overweight individuals.
NPM-139, a subdermal implant in development using the company's proprietary NanoPortal technology to deliver semaglutide, the active ingredient in Novo Nordisk's Ozempic/Wegovy.
Results from a preclinical study showed that treatment with NPM-139 resulted in nearly 20 percent weight loss from a single administration.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
"Products containing semaglutide generated $25 billion in 2024 and demand for these products continues to soar. Since over half of these patients regularl...